112.47  0.88 (0.79%)		08-28 16:02
Open: 111.6 High: 112.74 Volume: 7,520,601		Pre. Close: 111.59 Low: 111.11 Market Cap: 194,616(M)

Short term
Mid term
Targets	6-month :	137.05	1-year :	160.07
Resists	First :	117.33	Second :	137.05
Pivot price	112.73
Supports	First :	108.4	Second :	102.88
MAs	MA(5) :	114.18	MA(20) :	111.25
	MA(100) :	95.97	MA(250) :	110.1
MACD	MACD :	3.3	Signal :	3.8
%K %D	K(14,3) :	57.5	D(3) :	71.4
RSI	RSI(14): 59.6
52-week	High :	134.38	Low :	81.38

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABT ] has closed above bottom band by 47.1%. Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	112.79 - 113.47	113.47 - 114.13
Low:	109.49 - 110.3	110.3 - 111.07
Close:	111.21 - 112.4	112.4 - 113.54

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Fri, 28 Aug 2026
Precision Trading with Abbott Laboratories (ABT) Risk Zones - Stock Traders Daily

Fri, 28 Aug 2026
How Investors Are Reacting To Abbott (ABT) Dual Glucose‑Ketone Libre Duo FDA Greenlight - simplywall.st

Thu, 27 Aug 2026
Abbott (NYSE: ABT) CEO sells 398K shares after option exercise - Stock Titan

Thu, 27 Aug 2026
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up? - 24/7 Wall St.

Wed, 26 Aug 2026
What Does Abbott Laboratories (ABT) FDA Clearance Mean For Its Diabetes Device Push? - Yahoo Finance

Wed, 26 Aug 2026
Why Is Abbott Laboratories (ABT) Launching A First Of Its Kind Diabetes Wearable? - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	1,730 (M)
Shares Float	1,720 (M)
Held by Insiders	0.4 (%)
Held by Institutions	81.8 (%)
Shares Short	22,620 (K)
Shares Short P.Month	23,390 (K)

EPS	3.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	29.54
Profit Margin	11.6 %
Operating Margin	14.7 %
Return on Assets (ttm)	5.3 %
Return on Equity (ttm)	10.5 %
Qtrly Rev. Growth	13 %
Gross Profit (p.s.)	15.3
Sales Per Share	26.92
EBITDA (p.s.)	6.75
Qtrly Earnings Growth	-47.5 %
Operating Cash Flow	9,910 (M)
Levered Free Cash Flow	7,210 (M)

PE Ratio	36.39
PEG Ratio	2.2
Price to Book value	3.8
Price to Sales	4.17
Price to Cash Flow	19.63

Dividend	0.62
Forward Dividend	0
Dividend Yield	0.5%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.